DEENOVA
31.5.2022 06:02:12 CEST | Business Wire | Press release
Deenova reported today it recently beat its main competitors and was awarded a public tender for IRCCS Policlinico San Matteo named “Open telematic procedure for the acquisition of an integrated information system for the management of drug therapy and the traceability of drugs and medical devices ” by decree of the General Manager No. 5/D.G./334 as of March 18, 2022. This new Deenova customer in Italy includes the implementation and services for its many clinicians utilization at the point of care of 100 prescription trolleys, 100 administration trolleys, 100 barcode readers, 200 portable PCs, and 100 label printers.
Fulvio Rudello , Chief Operating Officer at Deenova stated: “This IRCCS Policlinico San Matteo is another testament of Deenova ´s Closed-Loop solutions undisputed European leadership in the healthcare industry. It cements the economic balance of continuing to add net new customers in Europe while at the same time proudly show a 100% retention rate of our existing customers, metrics that have no parallel in the health care sector.”
The IRCCS Policlinico San Matteo in Pavia has over 1,000 accredited beds serving 700.000 inhabitants in Lombardy, divided into about 60 operating units with teaching, health care assistance, and research activities. Among its units there are many areas of excellence, with approximately about 3,300 employees including doctors, nurses, technicians and administrators, offering 36,500 hospitalizations (13.7% of which to patients outside the region), 99.000 emergency room visits and 2.1 million outpatient visits.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005398/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gaétane Baudry Appointed Senior Vice President/Global General Manager, Bobbi Brown8.10.2026 14:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Gaétane Baudry as Senior Vice President/Global General Manager, Bobbi Brown, effective October 8, 2026. Based in New York, she will report to Lisa Sequino, Global President, Makeup Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008525584/en/ Gaétane Baudry In this role, Gaétane will lead Bobbi Brown’s global strategy and continued evolution, strengthening the brand’s distinctive equity, advancing innovation and creativity, and deepening consumer engagement around the world. “Gaétane is an inspiring and highly collaborative leader who brings experience, energy and a strong focus on execution,” said Lisa Sequino, Global President, Makeup Brands. “Her global brand-building record, strong commercial leadership and passion for creating meaningful consumer experiences will be invaluable as Bobbi Brown builds on its unique brand equity focused
Adtran launches Mosaic One Agents to help teams easily scale operations8.10.2026 14:00:00 CEST | Press release
News summary: Rapidly growing networks, operations and customer demands call for new ways to scale expertise Mosaic One Agents provides role-specific AI agent teams for network management, customer care and business operations Agent teams use data from Adtran and third-party hardware to investigate problems in parallel while organizations retain control Adtran today launched Mosaic One Agents, a suite of AI agents designed to help organizations scale expertise across network management, customer care and business operations. Built on Mosaic One Fabric, it gives role-based agent teams access to data from Adtran and third-party networks, enabling them to investigate issues, coordinate work across teams and drive issues through to resolution. By handling time-consuming investigation, coordination and process tasks, Mosaic One Agents helps people resolve issues faster, extend their expertise across more workflows and retain control of critical network and business actions. “When something
The LYCRA Company to Spotlight Renewable LYCRA® Fiber and Textile-to-Textile Circularity at Textile Exchange Conference 20268.10.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel and personal care industries, will showcase Renewable LYCRA® fiber and its work to advance textile-to-textile recycling at Textile Exchange Conference 2026. The conference takes place October 12–16, at the Vancouver Convention Centre in Vancouver, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008178765/en/ At the Textile Exchange Conference 2026, The LYCRA Company will showcase Renewable LYCRA® fiber and its progress in advancing textile-to-textile recycling. This year's theme, "The Implementation Era," focuses on scaling what works across businesses, supply systems, and landscapes. At the conference, The LYCRA Company will highlight its work with partners across the value chain, helping to shape the future for textiles through renewable fiber solutions, circular innovation, and strategic industry partnerships. “Bringing more rec
ARIS Strengthens Global Leadership Team with Three Senior Appointments to Accelerate 2027 Growth8.10.2026 14:00:00 CEST | Press release
Process Context Platform for Enterprise AI adds new Chief Product Officer, Global Head of Strategy & Transformation and Americas sales lead to help capitalize on growing enterprise demand for trusted, scalable AI ARIS, the global leader in Process Context for Enterprise AI, today announced three new senior appointments as it builds momentum toward 2027 and accelerates its strategy to help organizations put AI to work at scale. Maxime Hambersin joins as Chief Product Officer, Dr. Benjamin Krusche as Global Head of Strategy & Transformation, and Mark Jacobs as President and Go-to-Market Lead, Americas. The appointments further strengthen the leadership team built around CEO Guillaume Bacuvier and support the company's next phase of global growth. They come as ARIS advances its positioning around Process Context – giving AI agents the business understanding they need to operate effectively – while accelerating a product roadmap designed to help enterprises identify, deploy and scale AI ag
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 13:30:00 CEST | Press release
Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combinationArmenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance dataApprovals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastasesAgenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatell
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom